 Effect chemical conjugation recombinant single-chain urokinase-type plasminogen activator monoclonal antiplatelet antibodies platelet aggregation plasma clot lysis vitro vivo murine monoclonal antiplatelet antibodies human thrombospondin ligand-induced binding sites LIBS human platelet glycoprotein IIb/IIIa recombinant single-chain urokinase-type plasminogen activator rscu-PA cross-linking reagent N-succinimidyl propionate SPDP conjugates immunoadsorption gel filtration recoveries average stoichiometry IgG molecules rscu-PA molecule unaltered specific activities affinities Preincubation human platelet-rich plasma unconjugated rscu-PA partial inhibition ADP-induced aggregation inhibition micrograms/mL rscu-PA micrograms u-PA/mL micrograms u-PA/mL vitro system platelet-rich human plasma clot normal human plasma conjugates fibrinolytic potency unconjugated rscu-PA thrombolytic potency rscu-PA control conjugate pulmonary embolism model hamster clots platelet-poor platelet-rich human plasma Lysis minutes end intravenous infusion thrombolytic agents rscu-PA comparable thrombolytic potencies percent lysis dose platelet-poor human plasma clots contrast thrombolytic potency towards platelet-rich clots rscu-PA control conjugate